Construction of epigenetic biomarkers by regenerative indices of immune function

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07185
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kawasaki Medical School
• Principal Investigator: Tanioka Hiroaki 川崎医科大学, 医学部, 特任研究員 (40775491)
• Co-Investigator(Kenkyū-buntansha): 永坂 岳司 川崎医科大学, 医学部, 教授 (30452569) ; 岡脇 誠 川崎医科大学, 医学部, 講師 (40509254)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 胃癌 / バイオマーカー / 免疫チェックポイント阻害剤

Outline of Final Research Achievements

In the present study, we found that administration of Immune-checkpoint-blockade (ICB) to patients with unresectable advanced or recurrent gastric cancer altered the percentage of PD1-positive cells in the peripheral blood among CD8-positive T cells, the main target of ICB, before and after treatment.
The study showed that administration of Immune-checkpoint-blockade (ICB) to patients with unresectable advanced recurrent gastric cancer changed the percentage of PD1-positive cells in the peripheral blood among CD8-positive T cells, the main target of ICB, before and after treatment. There was also a trend toward greater efficacy of ICB treatment in patients with a higher percentage of PD1-positive cells before treatment. This suggests that the administration of ICB has some effect on Cytotoxic T lymphocytes in the peripheral blood.

Free Research Field

腫瘍内科学

Academic Significance and Societal Importance of the Research Achievements

本研究では末梢血中のCD8陽性T細胞中のPD1陽性細胞の割合や変化が切除不能進行再発胃癌に対するImmune-checkpoint-blockade （ICB）の効果予測因子になりうることが示唆された。このことは胃癌患者における免疫チェックポイント阻害の予後・効果予測因子を簡便に測定しうる可能性が示された。